Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and delivers therapies for treating ...

Shares of Biogen Inc. slipped 5.04% to $169.31 Wednesday, on what proved to be an all-around grim trading session for the ...

Shares of Biogen dipped after the biotechnology company said it expects to report a roughly $222 million pretax charge in the fourth quarter. Shares were down 5.9% to $167.88 on Wednesday morning. The ...

Biogen (NASDAQ:BIIB) traded ~8% higher in the premarket on Thursday after the company posted better-than-expected financials for Q2 2025, thanks mainly to a strong uptake for its Alzheimer’s therapy ...

CEO Chris Viehbacher told investors the company has worked to stabilize its business as its multiple sclerosis (MS) portfolio ...

Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all ...

Florida-based J. L. Bainbridge sold 119,376 shares of Biogen for an estimated $16.1 million in the third quarter. After the transaction, J. L. Bainbridge reported holding just 2,969 shares of Biogen ...

Biogen (NASDAQ:BIIB) is gearing up to announce its quarterly earnings on Thursday, 2025-10-30. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

Biogen and Eisai recently announced that Chinese regulators have accepted their Biologics License Application for a subcutaneous, at‑home injectable version of Alzheimer’s drug LEQEMBI, advancing it ...

Biogen Inc. (BIIB) came out with quarterly earnings of $3.02 per share, missing the Zacks Consensus Estimate of $3.26 per share. This compares to earnings of $3.67 per share a year ago. These figures ...

The U.S. Food and Drug Administration (FDA) stated on Thursday that it is requiring an additional MRI scan for Alzheimer's patients receiving Leqembi (lecanemab), citing safety concerns over a rare ...